GlobalData analysed the number of clinical trials examining ovarian cancer with start dates between 1 January 2009 and 21 January 2019.
Ovarian cancer occurs when abnormal cells start proliferating and eventually form a cancerous tumour. The term can cover a multitude of different cancers that affect the ovaries, fallopian tubes, and the primary peritoneal cavity.
According to the World Ovarian Cancer Coalition, ovarian cancer is the seventh most common cancer globally, the eighth most common cause of death for women, and tends to affect women ages 45 years of age and older.
Ovarian cancer screening has increased over the last decade. Depending on the stage of the cancer in question, the most common treatment procedure is having a radical hysterectomy (removal of the uterus, fallopian tube, and cervix) alongside chemotherapy.
Ovarian cancer can affect any woman, but studies have shown a correlation between mutations of the BRCA1 and BRCA2 gene and developing the cancer.
Biomarkers can play a very important role in making sure ovarian cancer trials come to completion. GlobalData analysed the four main leading biomarker roles for ovarian cancer studies (Figure 1).
The main purpose of biomarkers in ovarian cancer trials was found to be monitoring treatment response (78.9%). This was followed by having biomarkers involved in the inclusion criteria (18%), predicting treatment response (4.6%), and monitoring treatment safety (4.1%). The majority of analyzed ovarian cancer trials were in Phase II (53%), followed by Phase III (40.6%), Phase I (32.8%), and Phase IV (4.6%) (Figure 2).
Most of these trials were led by non-industry sponsors (57.8%). Among the top five countries to conduct ovarian cancer trials, the US had the highest rate at 80.0%.
Figure 1: Top four biomarker roles investigated in ovarian cancer trials
Figure 2: Ovarian cancer clinical trials initiated by phase